Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Pharmacol Ther. 2020 Mar 20;210:107525. doi: 10.1016/j.pharmthera.2020.107525

Fig. 6.

Fig. 6.

Analysis of ERO1α in cancer. A) Significant reduction in survival is observed for patients with high expression of ERO1α in glioma. B) ERO1A mRNA expression is significantly higher in more aggressive GBM gliomas than LGG. C) Significant reduction in survival is observed for patients with high ERO1A expression in KIRP. D) ERO1A mRNA expression is significantly higher in higher stages of KIRP. E) Significant reduction in survival is observed for patients with high ERO1A expression in LUAD. F) ERO1A mRNA expression is significantly higher in higher stages of LUAD. G) Significant reduction in survival is observed for patients with high ERO1A expression of in PAAD. H) ERO1A mRNA expression is significantly higher in increasing grades of PAAD. Kruskal-Wallis (KW) and survival analysis statistics were calculated using the R statistical programming language (Gravendeel, et al., 2009; Madhavan, et al., 2009).